Apnimed (APMD) director awarded 44,477 stock options at $16 strike
Rhea-AI Filing Summary
Apnimed, Inc. director William A. Jones Jr. reported derivative transactions involving stock options for 44,477 shares of common stock at an exercise price of $16.00 per share, expiring on July 29, 2036. The options are scheduled to vest in substantially equal monthly installments over 36 months after July 30, 2026, contingent on his continued service. The filing also notes a reclassification in which each share of Class A common stock was reclassified into one share of common stock pursuant to Rule 16b-7 and Rule 16b-3, which is described as an exempt reclassification.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
JONES WILLIAM A JR
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) F1, F2 | 44,477 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F1, F2 | 44,477 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F2 | 44,477 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 88,954 shares (Direct)
Footnotes (2)
- F1. Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.
- F2. The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Key Figures
Option Shares Granted: 44,477 shares
Exercise Price: $16.00 per share
Option Expiration: July 29, 2036
+1 more
4 metrics
Option Shares Granted
44,477 shares
Stock options reported for William A. Jones Jr.
Exercise Price
$16.00 per share
Conversion or exercise price of reported stock options
Option Expiration
July 29, 2036
Expiration date of the stock options
Vesting Period
36 months
Monthly vesting after July 30, 2026, subject to continued service
Key Terms
Rule 16b-7, Rule 16b-3, reclassification, vest and become exercisable
4 terms
Rule 16b-7 regulatory
"reclassification exempt under Rule 16b-7 and Rule 16b-3"
A U.S. Securities and Exchange Commission safe-harbor rule that shields corporate insiders (officers, directors and large shareholders) from automatic short-swing profit claims when they buy or sell their company’s stock under a pre-approved, written plan that follows specific timing and nondiscretionary rules. For investors, the rule matters because it distinguishes routine, formula-driven insider transactions from opportunistic trades that could trigger automatic profit recoveries—think of it as an approved autopilot for insider trading that reduces legal uncertainty when the plan’s conditions are met.
Rule 16b-3 regulatory
"reclassification exempt under Rule 16b-7 and Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
reclassification financial
"each share of Class A Common Stock was reclassified into one share"
Reclassification is the formal change in how an asset, liability, security, transaction, or business activity is labeled on financial records or under rules. It matters to investors because the new label can alter reported profits, tax treatment, ownership rights or perceived risk—much like moving an item from 'personal' to 'business' use, it doesn't create value by itself but can change comparisons, taxes, and who controls outcomes.
vest and become exercisable financial
"shares subject to such option vest and become exercisable in monthly installments"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Apnimed (APMD) director William A. Jones Jr. report?
Director William A. Jones Jr. reported stock option grants covering 44,477 shares of Apnimed common stock at an exercise price of $16.00 per share, expiring on July 29, 2036, with vesting over 36 months after July 30, 2026.
What is the exercise price and expiration date of the Apnimed (APMD) options?
The stock options reported for Apnimed have an exercise price of $16.00 per share and an expiration date of July 29, 2036. These terms apply to the 44,477 options granted to director William A. Jones Jr.
When do the Apnimed (APMD) stock options for William A. Jones Jr. vest?
The options vest and become exercisable in substantially equal monthly installments over 36 months after July 30, 2026. Vesting is conditioned on William A. Jones Jr.’s continuous service to Apnimed on each vesting date.
Were the Apnimed (APMD) insider option transactions under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and the footnotes do not reference any Rule 10b5-1 trading plan. The reported transactions are presented without an associated pre-arranged trading plan in this disclosure.